Giselle Mosnaim, MD, an allergist and immunologist at Endeavor Health, discusses Rhapsido® (remibrutinib), a new FDA-approved oral therapy for chronic ...
The Food and Drug Administration (FDA) has approved Eydenzelt ® (aflibercept-boav), a biosimilar to Eylea ® (aflibercept).
The approval was based on the C-POST study which evaluated cemiplimab in adults with CSCC at high risk of recurrence after surgery and radiation.
The risk for MASLD was significantly reduced by 14.7 and 13.5%, respectively, by replacing 330g/day of sugar-sweetened beverages or low- or non-sugar-sweetened beverages with water.
Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF.
The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.
Ambient trichloroethylene (TCE) is associated with an increased risk for Parkinson disease (PD), according to a study published online October 1 in Neurology. B ...
The Food and Drug Administration (FDA) has approved Zoryve ® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.
The same price is already available on Novo Nordisk’s direct-to-consumer website, as well as at Walmart and CVS.
Positivity decreased for 2vHPV, 4vHPV, and 9vHPV for vaccinated and unvaccinated participants from 2006 to 2023.
CDC approves new immunization schedule; new treatments approved for edema, idiopathic pulmonary fibrosis, and high risk cutaneous squamous cell carcinoma; ...
The FDA is expected to decide on treatments for achondroplasia, acute myeloid leukemia, familial chylomicronemia syndrome, immunoglobulin A nephropathy, and non-small cell lung cancer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results